Global, multi‑modal RWD —ready for evidence, analytics and more
Access granular, research‑ready real‑world data across key markets — curated to your specific needs and objectives — so you can move faster from questions to decisions.
The patient profiles you need
Use high-quality, anonymized longitudinal datasets that are curated to your inclusion / exclusion criteria, target geographies, and required modalities.
Robust multi‑modal data
Tap into structured and unstructured data that’s been harmonized, integrated, and ready to support advanced use cases.
- EHRs
- Labs and biomarkers
- Genomics / multi-omics
- Imaging
- eCRF data
- and more
Spanning multiple cancer types*
Focused on high-priority areas in your pipeline, including:
- Breast cancer
- Lung cancer
- Prostate cancer
- Kidney (renal) cancer
- Liver cancer
- Bladder cancer
*Other cancer types and disease areas also available
Support for advanced use cases
Advanced analytics
Accelerate cohort builds, reduce data wrangling and delays, and scale repeatable analytics across markets and modalities.
HEOR / market access
Generate robust country‑specific evidence, assess standard‑of‑care patterns, and support payer, HTA, and regulatory discussions.
Therapy area strategy
Map patient journeys, clarify biomarker and treatment landscapes, and inform portfolio / lifecycle decisions from early to late stage through post-launch.
Clinical development
Benchmark standard of care, validate endpoint feasibility, and stress‑test inclusion / exclusion criteria across countries — before protocol lock.